Weekly Watchlist and Review 12/10/23

Weekly Watchlist and Review

Welcome to the latest edition of our Weekend Watchlist and Review at ALERTSANDNEWS.COM. Last week’s market was a hotbed of activity with some remarkable movers and shakers. Let’s delve into the highlights of our recent alerts.

The market momentum was unparalleled. We started the week strong with SHOT, SSNT, ATHE, and VIEW, achieving targets across multiple plays. A perfect score of 6/6 on our buy alerts set the tone. Tuesday witnessed the precision of CMND and ALT, turning into veritable target-hitting machines. Midweek, we continued our streak with MLGO and SERA, along with more success from ALT, surpassing 30 targets and securing multiple winning buy alerts. Thursday was no different, with SVFD and SLDB hitting over 16 targets. Our swing on TGTX garnered an impressive 31% gain from our buy alert, and our overnight plays boasted an 83% win rate.

At ALERTSANDNEWS.COM, our accuracy is unparalleled. We offer a comprehensive range of services covering everything from momentum plays to dividend stocks. While we encourage doing your due diligence, for top-tier alerts and market insights, look no further. Our track record of success is a testament to our quality. To sweeten the deal, use code AAN10 for a 10% discount upon signing up. Elevate your trading expertise with us today!

Let’s start what to eye tomorrow, and the news over the weekend.

Here’s the Gappers from Friday. ONTX great alert here on Friday in after hours. They dropped a headline: 

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Solid pop right there from that headline, eye that one for continuation tomorrow morning. 

BTC has been showing some solid strength lately, sitting tight in a consolidation zone. It’s a good idea to keep an eye on it, as its movements often set the tone for all blockchain-related plays. This week, and especially tomorrow, we should closely watch stocks like MARA, RIOT, BTBT, EBON, and BITF. I’ll have a comprehensive list prepped and ready in the room before tomorrow’s session. Personally, I’m of the opinion that BTC might be gearing up to test the 50k mark soon.

Over the weekend, we saw a TON of headlines bio stocks. Mostly from this 2023 ASH meeting. Let’s take a look at them.

INCY: Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

TENB:Tenable Vulnerability Management And Tenable Web App Scanning, Have Been Successfully Assessed At A Protected Level By The Information Security Registered Assessors Program In Australia

LMT: Belgium and Lockheed Martin Celebrate Rollout of First F-35A for Belgium
 
CNTA :Centessa Pharmaceuticals Announced New Data From Additional 52-Weeks of Continuous Treatment From Third Year (Part 5) Of Ongoing Phase 2a Study Of SerpinPC For Treatment Of Hemophilia At 2023 ASH Meeting
 

MOLN: Molecular Partners Presented Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At 2023 ASH Meeting

APTO: Aptose Tuspetinib Clinical Data Featured In Oral Presentation Saturday At 2023 ASH Meeting; Said TUS/VEN Combination Active Across Broad Populations Of AML And Demonstrates 25% Complete Response Rate Among All-comers, Including 20% CRc In Wildtype AML

REGN: Regeneron Announced Sunday Updated Odronextamab Data From Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep And Durable Responses And Potential Of ctDNA To Predict Long-term Outcomes At 2023 ASH Meeting

BLTE: Belite Bio Received Approval To Initiate Tinlarebant Phase 3 Clinical Trial For GA in Switzerland

BLUE:Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

VINC: Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

ACET: Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

GLYC GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

PSTX: Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

IMGN ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

JSPR: Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

BMY: Bristol Myers Squibb On Saturday Presented Primary Efficacy, Safety Analysis of the Phase 3 COMMANDS Trial Of Reblozyl For Treatment Of Anemia In Erythropoiesis Stimulating Agent-Naïve Patients With Lower-Risk Myelodysplastic Syndromes At 2023 ASH Meeting

FGEN: FibroGen Presented Data From Phase 3 MATTERHORN Trial Of Roxadustat In Patients With Anemia Of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes At 2023 ASH Meeting

BMEA: Biomea Fusion Announced Saturday Near Doubling The Percentage Of Patients With Durable HbA1c Reduction In the 200 mg Dose Cohorts

AGIO: Agios Presented Results Saturday From Phase 2 Portion Of RISE UP Pivotal Study In Sickle Cell Disease At ASH Meeting; Said Treatment With Mitapivat Demonstrated Statistically Significant Improvement In Hemoglobin Response Compared To Placebo

IPHA: Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

AUTL: Autolus Therapeutics Presented Clinical Data Updates Saturday At 2023 ASH Meeting

NKTX: Nkarta Presented NKX101 Clinical Data Saturday At 2023 ASH Meeting

GMAB/BMY: Genmab, AbbVie On Saturday Announced New Pivotal Data for Bispecific Antibody Epcoritamab CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

COGT: Cogent Biosciences Announced Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib In Patients with Nonadvanced Systemic Mastocytosis 57% Median Best Improvement On MC-QoL And 78% Of Patients Reporting ≥1 Point Improvement On PGIS By Week 20

TCRX: TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

IPSC: Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

ADPT: Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

  • Chinese CPI YoY Actual -0.5% (Forecast -0.2%, Previous -0.2%)
  • Chinese PPI YoY Actual -3% (Forecast -2.8%, Previous -2.6%)
  • Harvard Rocked by Attacks on President After Penn Leader Quits
  • Zelenskiy to Meet Biden, Senators as US Aid to Ukraine in Limbo
  • Elon Musk reactivates Alex Jones’ X accounts after a five-year ban
  • US beginning internal discussions about renewing North American trade pact – CBC News

     

  • EU clinches deal on landmark AI Act

 

News Coming:

By staying informed about the FDA decisions and other news, investors, healthcare professionals, and patients can gauge the potential impact on the pharmaceutical industry, stock market, and patient care. These decisions can influence the market value of pharmaceutical companies. Let’s look at the news coming: 

 


Stock TickerCompany NameDecision DetailsEstimated Decision Date
TSVT2seventy bio, Inc.

FDA decision on the expanded use of Abecma in triple-class exposed relapsed and refractory multiple myeloma patients, who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

UPDATE: On Nov.20, 2023, the company announced that an FDA panel is expected to review the sBLA and therefore a decision is unlikely to be made on the assigned PDUFA date

12/16/2023
OPTNOptiNose Inc.FDA decision on the expanded use of XHANCE in treating adults with chronic rhinosinusitis12/16/2023
ARQTArcutis Biotherapeutics Inc.FDA decision on Roflumilast Foam 0.3% for treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older12/16/2023
ARQTArcutis Biotherapeutics Inc.FDA decision on Roflumilast Foam 0.3% (NDA) for treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older12/16/2023
CALTCalliditas Therapeutics AB (publ)FDA decision to convert accelerated approval of TARPEYO to full approval to reduce proteinuria in adults with primary IgA nephropathy (sNDA)12/20/2023
IONSIONIS PHARMACEUTICALS INCFDA decision on eplontersen for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)12/22/2023
AMGNAmgen Inc.FDA decision on converting approval of Lumakras from accelerated approval to full approval12/24/2023
CKPTCheckpoint Therapeutics, Inc.FDA decision on Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma01/03/2024
FBIOFortress Biotech Inc.FDA decision on Cosibelimab as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma01/03/2024

Let’s look at some oversold and/or highly shorted stocks. 

Grasping the dynamics of oversold and heavily shorted stocks is key for traders and investors looking to capitalize on emerging opportunities. Oversold stocks can be hidden gems, potentially undervalued due to market overreaction. On the other hand, stocks with high short interest are prime candidates for a short squeeze, a situation where a swift price surge happens as short sellers rush to close their positions. 

SOND, SOND’s looking pretty rough these days, with its float around 8M and about 10% shorted. The Stoch RSI is way down in the dumps, and the MACD’s hinting at a possible cross. All eyes should be on the volume ratios now. If they pick up, we might see SOND bounce back from the beating it’s taken. Definitely one to watch for a potential rebound.


LQR: is back on our watchlist for the second week, and it’s really been taking a beating. The stock’s been nose-diving, especially after a recent reverse split. Its RSI is scraping the bottom, indicating it’s seriously oversold. This one’s a prime candidate to keep on the radar, as its current state could lead to some interesting moves. Definitely worth watching to see if it can see a volume surge. 

FSR: This is also making its second appearance on our watchlist. She noticed a spike in volume on friday last week, which is interesting considering it’s heavily shorted. About 41% of the float. It’s been on a bit of a nosedive lately, but that kind of short interest can lead to some unpredictable moves. Definitely worth keeping an eye on FSR to see how it unfolds in the coming days.

THAR: Another stock that’s been through the wringer recently, especially after a recent split. It’s in desperate need of some trading volume to turn things around. Right now, it’s incredibly oversold, so keeping a close watch on the volume ratios is key. There could be an opportunity if the activity picks up. Definitely worth continuing to monitor THAR for any signs of life or potential shifts in momentum.

Oversold beat up stocks to eye,

EGRX, VTYX, NVOS, SEEL, CHPT, NNDM, LAC, LAZR.

Earnings Calender:

Economic Calendar and Futures.

Upcoming Economic Events for the Week of December 11th-15th

TIME (ET)REPORTPERIODACTUALMEDIAN FORECASTPREVIOUS
MONDAY, DEC. 11     
 None scheduled    
TUESDAY, DEC. 12     
8:30 amConsumer price indexNov. 0.0%0.0%
8:30 amCore CPINov. 0.3%0.2%
8:30 amCPI year over year  3.0%3.2%
8:30 amCore CPI year over year  4.0%4.0%
2:00 pmMonthly U.S. federal budgetNov. -$250B-$249B
WEDNESDAY, DEC. 13     
8:30 amProducer price indexNov. 0.1%-0.5%
8:30 amCore PPINov. 0.1%
8:30 amPPI year over year  1.3%
8:30 amCore PPI year over year  2.9%
2:00 pmFOMC interest-rate decision    
2:30 pmFed Chairman Jerome Powell press conference    
THURSDAY, DEC. 14     
8:30 amInitial jobless claimsDec. 9 220,000220,000
8:30 amImport price indexNov. -0.9%-0.8%
8:30 amImport price index minus fuelNov. -0.2%
8:30 amU.S. retail salesNov. -0.1%-0.1%
8:30 amRetail sales minus autosNov. 0.1%0.1%
10:00 amBusiness inventoriesNov. 0.0%0.4%
FRIDAY, DEC. 15     
8:30 amEmpire State manufacturing surveyDec. 3.59.1
9:15 amIndustrial productionNov. 0.2%-0.6%
9:15 amCapacity utilizationNov. 79.1%78.9%

In the second week of December, Wall Street and economic analysts will closely monitor a range of key economic indicators that could shape market sentiment and monetary policy in the near future. The week begins quietly with no major reports scheduled for Monday, December 11.

Tuesday, December 12, will bring a focus on inflation with the release of the Consumer Price Index (CPI) for November. Analysts expect a flat reading of 0.0%, mirroring the previous month. Core CPI, which excludes volatile food and energy prices, is anticipated to rise slightly to 0.3% from 0.2%. Year-over-year figures are expected to show a slight easing, with CPI predicted at 3.0% and Core CPI at 4.0%, both maintaining their previous levels. Later in the day, the U.S. federal budget for November will be released, with forecasts suggesting a deficit of around -$250 billion, slightly more than the previous month’s -$249 billion.

Wednesday, December 13, is a pivotal day with the release of the Producer Price Index (PPI) for November. A modest increase of 0.1% is expected, contrasting the previous month’s decline of -0.5%. Core PPI figures are also due, with year-over-year data eagerly awaited by investors. The day culminates with the highly anticipated FOMC interest rate decision and Fed Chairman Jerome Powell’s press conference, which could provide critical insights into the Fed’s view on the economy and future monetary policy.

On Thursday, December 14, attention turns to labor and trade with the release of initial jobless claims for the week ending December 9, anticipated to remain steady at 220,000. The Import Price Index is expected to show a further decline of -0.9%, indicating continued adjustments in international trade dynamics. Retail sales data for November will also be scrutinized for consumer spending trends, with a predicted slight drop of -0.1% in overall retail sales and a 0.1% increase in retail sales minus autos.

The week concludes on Friday, December 15, with the Empire State Manufacturing Survey for December, where a reading of 3.5 is expected, down from 9.1, potentially reflecting a cooling in the manufacturing sector. Industrial production and capacity utilization figures for November will round off the week, with forecasts suggesting a modest rebound in production and a slight increase in capacity utilization.

Overall, this week’s economic reports are crucial for investors to gauge the health of the U.S. economy amid ongoing discussions about inflation, consumer behavior, and the Federal Reserve’s policy direction.

As of 6:34 PM EDT, market futures are mixed but mostly green. Thanks for reading. For more targeted insights and timely alerts, make sure to check us out at alertsandnews.com Don’t forget to use the promo code AAN10 for 10% discount on all our packages. Getting the team the first mover advantage. Get informed first with your command center for the markets. Don’t let the next big opportunity pass you by! Join the team today!

DISCLAIMER

The forum, blog, watchlist and chatrooms on the Site are comprised of customers and members (including, without limitation, moderators who are in the employ of Alerts and News) posting content and information. All such information and content is for informational purposes only and does not constitute advice or a recommendation by Alerts and News to enter into any securities transactions or engage in any of the financial strategies reflected on or suggested in forum, blog, watchlist and chatrooms (whether such data, content or information is posted by Alerts and News or otherwise). Customers and members may write about securities in which they have a financial or other interest, and performance data reflecting other customer’s or member’s holdings may include information about securities not held by Alerts and News or its directors, officers, shareholders, employees, agents or affiliates. As such, Alerts and News is not responsible for the accuracy of data, content or information or any performance data in any forum, blog, watchlist and chatrooms; and the accuracy of data, content or information or any performance data are not guaranteed, may not be current and should not be relied upon. Nothing in any forum, blog, watchlist and chatrooms is intended as, nor should you rely on it as, investment advice provided by Alerts and News or its directors, officers, shareholders, employees, agents or affiliates. AlertsAndNews receives cash compensation for referring potential clients to Benzinga LLC via advertisements placed on their website. AlertsAndNews’s opinions are their own.

Take your trading to the next step!

Try a trial – for less than a cup of coffee

Shopping Cart
Scroll to Top